Date: 2015-07-13
Type of information: Nomination
Compound:
Company: Alcobra (Israel)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 13, 2015, Alcobra, an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced that all proposals were approved at the Company\'s annual meeting held today in Tel Aviv, including the election of Dr. João Siffert to its Board of Directors. Dr. Siffert brings over 20 years of executive-level pharmaceutical industry and clinical experience. He currently serves as the Executive Vice President of Research and Development and Chief Medical Officer (CMO) of Avanir Pharmaceuticals Inc. (subsidiary of Otsuka Pharmaceutical). Dr. Siffert joined Avanir in August 2011 and has led therapeutic development programs in dementia, depression, neuropathic pain, migraine and Parkinson\'s disease. Dr. Siffert previously served as VP and CMO at Ceregene, Inc., focused on the development of neurotrophic gene therapies for Alzheimer\'s and Parkinson\'s disease. Prior to this position, he served as the CMO at Avera Pharmaceuticals and held several positions with Pfizer. Dr. Siffert held academic positions at Beth Israel Medical Center and Albert Einstein College of Medicine, and completed residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert holds an M.D. from the University of São Paulo, Brazil and an M.B.A. from the Columbia University Graduate School of Business in New York.
Financial terms:
Latest news:
